MANILA, Philippines — IP Biotech Inc. (IPB), in partnership with Ambica International Inc., announced on Saturday they are interested in applying for clinical trials for ivermectin with the Food and Drug Administration (FDA).
“IPB and Ambica seek to work closely with regulators and an independently run clinical trial to validate ivermectin as a treatment for COVID19.” IPB Chairman Enrique Gonzales said in a statement on Saturday, April 10.
IPB said a number of physicians in the country are recommending the use of ivermectin in the treatment against COVID-19, saying the antiparasitic drug has been used to treat COVID-19 patients in Honduras and other regions of the world.
“…
Keep on reading: PH biotech firm, pharma group eye clinical trials for ivermectin use against COVID-19